Nature knows how
it’s supposed to work.
So do we.
PaxosMedical exists because catheterization is not a solution — it is a sentence. And for 20+ million Americans living with Underactive Bladder, that sentence has no expiration date. We are here to end it.
We build implantable neuromodulation therapies that restore what the body was designed to do: void naturally, voluntarily, completely — on the patient's own terms. Our lead product, UnderControl™, activates the voiding neural circuit through a patented mechanism developed over 40 years at Duke and Pittsburgh. It is designed to be placed in an outpatient procedure, activated by the patient, and reimbursed through existing CPT codes. No new catheter. No new training. No more planning every day around a supply bag and a clean bathroom.
Paxos was built by people who have spent careers in neuromodulation and are done watching meaningful science get slow-walked by institutions that have stopped being curious. We move with urgency because patients are waiting. We work with rigor because these devices go inside people. We hire only people we want to work with, because the quality of the team is the quality of the therapy. And we believe — with full confidence in the preclinical data, the patent, and the path to market — that the body's freedom is worth fighting for.
How UnderControl™ works:
-
The wave that changes everything. The activation signal is not metaphor — it is the mechanism. Paxos Medical's first pillar is the neural signal that restores natural function: precise, targeted, patient-controlled. Signal is what separates Paxos Medical from every suppressive competitor in the market, and it belongs to the patient the moment they choose to send it.
-
The cracked earth breaks open when water arrives. Paxos Medical breaks the silence around UAB and catheterization. This is a company willing to say the uncomfortable thing plainly and build the therapy nobody else pursued — because it was too hard, too new, and too far from the incrementalism that dominates medtech.
-
The restored, natural state. After the signal, after the break, comes flow — voluntary, complete, and on the patient's own terms. Flow is both physiological truth and the felt experience of freedom: travel returned, sleep returned, spontaneity returned. The body doing what nature intended, at the moment the patient decides.
PaxosMedical
Leadership Team
Jeff Erb, MBA
-
Mr. Erb has spent multiple decades in the medical device industry including almost 20 years at Medtronic and later in multiple early-stage neuromodulation companies. During his time at Medtronic, he served in multiple senior level roles including Corporate Development, Business Development, Alliance Management, IP Portfolio Management, Strategy and Marketing for Medtronic's Corporate, Cardiovascular, and Neuromodulation sectors. In his last 10 years at Medtronic, Jeff led Strategy and Business Development for Medtronic's Neuromodulation sector which included Brain Stimulation, Pain Stimulation and Pelvic Health. After leaving Medtronic, he has served in executive roles at multiple early-stage neuromodulation companies including CEO, Board of Directors, Chief Business Officer, and Strategic Advisory roles. Jeff has undergraduate degrees in economics and business administration from the University of Pittsburgh and an M.B.A. from the University of Michigan.
Jon Ruais, MBA
-
Mr. Ruais brings nearly two decades of commercial leadership experience across the medical device and life sciences industries, with deep expertise in neuromodulation commercialization. Jon began his career as a Submarine Officer in the United States Navy before transitioning to the medical device industry. Most recently, he served as Chief Commercial and Strategy Officer at Nalu Medical, where he built the commercial organization from the ground up and developed rapid market growth strategies for peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS). Prior to Nalu, Jon held commercial and strategic roles at St. Jude Medical, Opsens Inc., Diadexus, and Thoratec Corporation, spanning neuromodulation, cardiovascular, diagnostics, and interventional device markets. Jon studied at The George Washington University, Oxford University, and received an M.B.A. from University of West Florida.
Matt Fraser, PhD
-
Dr. Fraser is a classically trained physiologist and neuroscientist who has spent his career at the intersection of basic science research and therapeutic development for pelvic and urological dysfunction. He served as Associate Professor and Director of Basic Science Research in the Division of Urology at Duke University Medical Center and the Durham VA Medical Centers, where he directed the Laboratory of Neurourology. His research has focused on neurostimulation therapy for overactive and underactive bladder, neurogenic bladder secondary to spinal cord injury and traumatic brain injury, and novel therapeutic approaches including pharmacological, medical device, cell therapy, and tissue engineering methods. Intellectual property developed in his Duke and VA laboratory directly supports Paxos Medical’s technology platform. Dr. Fraser co-founded and served as Director of InVivo Pharmacology for Dynogen Pharmaceuticals and Urogenix Inc from 2002-2009. He also co-founded and served as the President of the Society for Pelvic Research from 2015 to 2019. Dr. Fraser holds a PhD in physiology with a neuroscience focus from the University of Pittsburgh School of Medicine.
Ben Tranchina
-
Mr. Tranchina has more than 25 years of technology business leadership experience across early-stage and multinational commercial medical device companies, with approximately 30 issued or pending patents relevant to neuromodulation. He served in various leadership roles over nine years at Advanced Neuromodulation Systems, Inc. and St. Jude Medical, where he led the development of nine first-to-market products. Ben later served as Chief Technology Officer of Neurotechnology Innovations Translator (NIT), LLC, and as CEO of NIT portfolio company Veressa Medical, where he led development of an innovative peripheral nerve stimulation system for the treatment of pelvic floor dysfunction and peripheral pain. He subsequently served as Chief Technical Operations Officer at Nuvectra Corporation. Most recently, Ben has served as Chief Executive Officer of IC Enable a microelectronics solution provider to high reliability markets such as Medical, Defense and Aerospace. He holds a Master's degree from the University of Texas at Dallas in microelectronic systems.
Jeff Kramer, PhD
-
Dr. Kramer has more than 25 years of experience conducting both basic and clinical neuroscience research, with a focus on translational approaches to clinical problems in sensory, motor, and autonomic dysfunction. He has built successful research programs in academic, startup, and large corporate environments, all aimed at developing new and improved neuromodulation therapies. Jeff joined Spinal Modulation in 2009 to build the company’s pre-clinical and clinical research efforts, and later served as Vice President and Fellow at St. Jude Medical and Vice President, Research & Technology at Medtronic. He is the Founder of Volta Research and Consulting, is extensively published and has been an invited speaker at several major neuromodulation conferences. Dr. Kramer received his PhD in Molecular and Integrative Physiology from the University of Illinois at Urbana-Champaign.
Eric Bosler, MBA
-
Mr. Bosler brings 30+ years financial leadership experience across the medical device and healthcare technology industries. Eric has extensive experience building companies with over $100M in capital raised. He has served as Chief Financial Officer at multiple companies including ABOUT Healthcare, HistoSonics, Zipnosis and SurVivaLink. Early in his career, over a twelve year period, Eric held senior finance roles at Medtronic spanning commercial operations, R&D and manufacturing. He began his career at EY. Eric holds a Bachelor of Arts from Colorado State University and a Master of Business Administration from the University of Denver – Daniels College of Business.
Orlando Flores
-
Mr. Flores brings over two decades of legal and compliance leadership in the medical device industry. He spent 18 years at Medtronic, where he held progressively senior roles including Chief Counsel to the Deep Brain Stimulation division, lead counsel to Medtronic’s Neuromodulation business development function, and Compliance Officer to the Latin America and Americas Regions, where he built and led legal and compliance teams across multiple geographies. His expertise spans business development transactions, business legal counseling, ethics and compliance program development, and business combinations in the medical device industry. Prior to Medtronic, Orlando practiced as a corporate attorney at Dorsey & Whitney LLP. Most recently, he serves as Global Ethics & Compliance Officer at a commercial-stage medical device company as well as counsel to medical device start-ups. He holds a Juris Doctor from the University of Minnesota Law School.
John Swoyer
-
Mr. Swoyer is a seasoned medical device executive with extensive experience in the development and commercialization of implantable neuromodulation and gastric stimulation therapies, supported by a portfolio of over 90 issued U.S. patents. He recently served as Chief Technology Officer at Enterra Medical, where he led technology development for the Enterra Therapy gastric electrical stimulation system. Previously, John served as Vice President of Engineering at Nextern, overseeing cross-functional teams developing wearable, at-home, and implantable products including neurostimulators. He held the role of Vice President, Technical Operations at Nuvectra, and served as Executive Director of Product Development at Integer Holdings, where he led a multi-location team through FDA submission and CE Mark approval for a spinal cord stimulation system. Earlier in his career, John spent significant time at Medtronic as a Technical Fellow and Manager of Product Development in the Gastro Uro division. He holds a Master of Science in Technology Management from the University of St. Thomas.
PaxosMedical
Advisory Board
Christopher Chapple, MD
Urological Surgeon
Sheffield Teaching Hospitals; Secretary General, EU Association of Urology; Editor-in-chief Journal Neurology and Urodynamics; editorial board of several journals such as the British Journal of Urology, European Urology
Colin Goudelocke, MD
Urological Surgeon
Department of Urology at Ochsner Medical Center in New Orleans; Founding member of the UT Erlanger Department of Urology; Founder of the Overactive Bladder Clinic, among the nation’s first such clinics
Arun Sahai, MD
Urological Surgeon
Guy’s & St Thomas' NHS Foundation Trust; Senior lecturer at King's College London British Association of Urological Surgeons committee of female, neurological and urodynamic urology; frequent reviewer and editor of many international urology journals
Kenneth Peters, MD
Urological Surgeon
Chairman of the Department of Urology at Beaumont Hospital, Royal Oak MI; Medical Director of the Beaumont Women’s Urology & Pelvic Health Center; Professor & Chair of Urology, Oakland University William Beaumont School of Medicine
Sachin Malde, MD
Urological Surgeon
Guy’s & St Thomas' NHS Foundation Trust; European Association of Urology guidelines; National specialist training: the British Association of Urological Surgeons; Royal College of Surgeons; Royal Society of Medicine
Ending the tyranny of the catheter.
Restoring control, on demand.